1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014

Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014

  • October 2014
  • -
  • Global Markets Direct
  • -
  • 45 pages

Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014’, provides an overview of the Nerve Gas & Pestiside Poisioning’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nerve Gas & Pestiside Poisioning
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Nerve Gas & Pestiside Poisioning and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Nerve Gas & Pestiside Poisioning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nerve Gas & Pestiside Poisioning pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nerve Gas & Pestiside Poisioning
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nerve Gas & Pestiside Poisioning pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Nerve Gas and Pestiside Poisioning - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nerve Gas and Pestiside Poisioning Overview 6
Therapeutics Development 7
Pipeline Products for Nerve Gas and Pestiside Poisioning - Overview 7
Pipeline Products for Nerve Gas and Pestiside Poisioning - Comparative Analysis 8
Nerve Gas and Pestiside Poisioning - Therapeutics under Development by Companies 9
Nerve Gas and Pestiside Poisioning - Therapeutics under Investigation by Universities/Institutes 10
Nerve Gas and Pestiside Poisioning - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Nerve Gas and Pestiside Poisioning - Products under Development by Companies 13
Nerve Gas and Pestiside Poisioning - Products under Investigation by Universities/Institutes 14
Nerve Gas and Pestiside Poisioning - Companies Involved in Therapeutics Development 15
Baxter International Inc. 15
Teva Pharmaceutical Industries Limited 16
PharmAthene, Inc. 17
Protalix BioTherapeutics, Inc. 18
PlantForm Corporation 19
Nerve Gas and Pestiside Poisioning - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
atropine sulfate - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
PRX-105 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Plasma Derived Butyrylcholinesterase - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Second Generation Protexia - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Peptides for Nerve Gas and Pestiside Poisioning - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Recombinant Butyrylcholinesterase - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Nerve Gas and Pestiside Poisioning - Recent Pipeline Updates 36
Nerve Gas and Pestiside Poisioning - Dormant Projects 38
Nerve Gas and Pestiside Poisioning - Product Development Milestones 39
Featured News and Press Releases 39
Sep 08, 2014: PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs 39
Jun 11, 2013: Therapure Biopharma Receives Subcontract Award From DynPort For Development Of Anti-Nerve Gas Agent 40
May 23, 2013: AIBioTech Receives Subcontract Award From DynPort For Continued Development And FDA Approval Of Nerve Agent Prophylactic 40
May 09, 2013: DynPort Vaccine Receives US Army Contract Worth $156.6m To Develop Nerve Gas Prophylactic 41
Apr 17, 2013: PharmAthene's Recombinant Butyrylcholinesterase Successfully Targets Nerve Agents In In-Vitro Study 41
Oct 24, 2011: Aeolus Announces NIH Counteract Grant Award To Develop AEOL 10150 As Treatment Against Nerve Agent Exposure 42
Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables

Number of Products under Development for Nerve Gas and Pestiside Poisioning, H2 2014 7
Number of Products under Development for Nerve Gas and Pestiside Poisioning - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Nerve Gas and Pestiside Poisioning - Pipeline by Baxter International Inc., H2 2014 15
Nerve Gas and Pestiside Poisioning - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 16
Nerve Gas and Pestiside Poisioning - Pipeline by PharmAthene, Inc., H2 2014 17
Nerve Gas and Pestiside Poisioning - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 18
Nerve Gas and Pestiside Poisioning - Pipeline by PlantForm Corporation, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Nerve Gas and Pestiside Poisioning Therapeutics - Recent Pipeline Updates, H2 2014 36
Nerve Gas and Pestiside Poisioning - Dormant Projects, H2 2014 38

List of Figures

Number of Products under Development for Nerve Gas and Pestiside Poisioning, H2 2014 7
Number of Products under Development for Nerve Gas and Pestiside Poisioning - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Target, H2 2014 21
Number of Products by Stage and Top 10 Target, H2 2014 22
Number of Products by Top 10 Mechanism of Action, H2 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 24
Number of Products by Top 10 Route of Administration, H2 2014 25
Number of Products by Stage and Top 10 Route of Administration, H2 2014 26
Number of Products by Top 10 Molecule Type, H2 2014 27
Number of Products by Stage and Top 10 Molecule Type, H2 2014 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.